The effect of the quadruple regimen containing rosuvastatin on the improvement of stomach infectio

Phase 3

• Conditions: Helicobacter pylori.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20230314057717N2
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

Confirmation of H. pylori infection in patients by standard diagnostic methods
Age above 18 years
Willingness to participate in the study

Exclusion Criteria

Patients are currently being treated with a four-drug regimen

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Helicobacter pylori eradication. Timepoint: Before the intervention and 14 days after the intervention. Method of measurement: Endoscopy or fecal antigen test.

Secondary Outcome Measures

Name	Time	Method
Occurrence of drug side effects. Timepoint: 14 days after the start of the intervention. Method of measurement: Physical examination.